Charles River Labs climbs as divestiture-driven margin story gains traction near $185
Charles River Laboratories shares rose about 3.4% to around $185 as investors focused on renewed bullish analyst commentary following the company’s portfolio-sharpening divestiture plan. Recent updates outlined Q2 2026 closings for asset sales, with management guiding to at least 100 bps of non-GAAP operating-margin improvement in 2026 and modest EPS accretion.
1. What’s moving the stock
Charles River Laboratories International (CRL) is trading higher Friday as the market re-prices the company around a cleaner, higher-margin profile after its recent planned divestitures and related guidance updates. The move comes as investors digest the company’s plan to sell its CDMO and Cell Solutions businesses and certain European Discovery Services assets, transactions expected to close in the second quarter of 2026, and as bullish sell-side notes continue to circulate raising targets and emphasizing a valuation discount versus peers. (biospace.com)
2. The catalyst: divestitures and updated 2026 guide
In its February 25, 2026 update, Charles River said it signed definitive agreements to divest (1) its CDMO and Cell Solutions businesses to GI Partners mainly for future contingent performance-based payments and (2) certain European Discovery Services assets to IQVIA for about $145 million in cash plus up to $10 million in additional payments. The company said the deals should reduce 2026 reported revenue by a little more than $200 million, but are expected to deliver at least 100 basis points of incremental non-GAAP operating-margin improvement in 2026 and add about $0.10 to non-GAAP EPS for the partial year, lifting its non-GAAP EPS range to $10.80–$11.30 (assuming Q2 closings). (biospace.com)
3. Why sentiment is improving now
Analyst commentary has increasingly framed the story as “sharpened focus” plus margin uplift, with recent target increases keeping attention on upside from execution rather than top-line growth. For example, Barclays raised its price target to $210 from $200 while maintaining an Overweight rating, reinforcing the near-term narrative that portfolio reshaping and efficiency actions can drive better profitability even in a cautious demand backdrop. (tipranks.com)
4. What to watch next
Key near-term signposts are (1) confirmation that both transactions close on schedule in Q2 2026, (2) management’s ability to deliver the expected margin lift while navigating the revenue step-down, and (3) any updates on longer-term targets that management has said will be discussed at an upcoming 2026 Investor Day. Investors will also monitor capital-allocation choices as proceeds come in and the company continues broader strategic actions tied to its review process. (biospace.com)